For Volunteers and Participants
Frequently Asked Questions on Alzheimer’s Disease and Dementia
1. What are the common symptoms of Alzheimer’s disease?
2. Is dementia inevitable in old age?
3. When does dementia start?
4. If dementia usually starts only around 60 years of age, why does CBR recruit volunteers who are 45+ years old?
5. I read that currently there is no cure for Alzheimer’s disease. If there is no cure, why is the study conducted?
6. Is there any scope for reversal of the damage with proper medication?
7. How to address the stress on care givers?
Caring for someone with Alzheimer’s disease or another type of dementia can be a long, stressful, and intensely emotional journey. As our loved one’s cognitive, physical, and functional abilities gradually diminish over time, it is natural to become disheartened, overwhelmed, and neglect our own health and well-being. There are several healthy practices that caregivers can adopt to look after their own physical and emotional health.
The second step is to set SMART goals for care-giving: goals that are Specific (well-defined and clear), Measurable (there is a criterion that measures progress towards the goal), Achievable (attainable), Realistic (within reach) and Timely (has a well-defined timeline). An example of a SMART goal: say you want to help your loved one to walk to the gate of your house to pick up the newspaper every morning. You could measure this goal by looking into the level of assistance they needed or the time they took to stand up, and set a realistic timeframe (say, 2 or 3 weeks) to expect improvement.
One could also consider consulting a mental health professional (a psychologist or a psychiatrist), if required, because reaching out for help is crucial. It is important to realize that only when we are healthy and are taking good care of ourselves can we care for another person.
8. How can a family manage or handle elders suffering from dementia?
While there is no clear cure for dementia as of now, researchers around the world are working towards treatments that can delay the disease and improve the lives of millions. While it is a long and challenging road ahead for a caregiver of a dementia patient, being positive and hopeful through the process goes a long way. Treatment begins by attempting to enrich the environment and daily activities of the person with dementia. Attempting to engage the patient in activities they previously enjoyed (keeping in mind diminished cognitive capacity) is important. Sometimes, they might respond better to a non-family caregiver when it comes to initiating and participating in activities. Community-based day programs are spaces for patients to engage in a variety of social, cognitive, and physical activities. Caregivers can provide positive feedback and ‘rewards’ for engaging in activities can often help to ensure sustainability of benefits.
9. How/where do we find care-givers?
10. Are there health schemes to support persons with disabilities/dementia?
11. What is the government’s action on dementia care?
In response to the growing number of people affected with dementia at the state and national levels, The Dementia India strategic plan is envisioned as an initial step to bring transformation in ensuring comprehensive dementia services. This outlines the government’s plan to commit resources that are necessary to address the problems of dementia. This national strategic plan is expected to receive a commitment from the government on yearly basis for funding, capacity-building, and research to transform the dementia care and support services at state and national levels.
12. Is there any relationship between cardiac disease and dementia?
Research has shown that people with cardiovascular risk factors such as cardiac arrest, stroke, high blood pressure, and dyslipidemia, have higher chance of developing dementia.
13. Should therapy include mental activities?
14. Can we try electrical stimulation for Alzheimer’s disease?
15. What is the role of stress in the onset of Alzheimer’s?
16. Does staying alone with limited interactions with others contribute to Alzheimer’s disease?
17. Will reading help?
18. Where can we find financial help for people with Alzheimer’s disease or their caregivers?
Pradhan Mantri Jan Arogya Yojana (PMJAY) is the world’s largest health assurance scheme, aimed at providing a health cover of INR 5 lakhs per family per year for secondary and tertiary care hospitalization which also includes dementia. However, only vulnerable and BPL families are eligible for this scheme.
Section 80DDB of income tax act provides tax deduction to individuals for medical expenses incurred for treatment of specified diseases or ailments such as dementia. A maximum deduction amount of INR 40,000 can be claimed by individuals who are less than 60 years of age, and a maximum of INR 1 lakh can be claimed by senior citizens.
19. I heard that pranayama and yoga reduce the risk of dementia. Does CBR study the role of pranayama?
The ongoing studies at CBR are observational studies and do not include pranayama/yoga or any other interventional component. Going forward, CBR is planning to conduct a multimodal interventional trial for the prevention of dementia. The objective of the trial is to understand the potential effects of interventions such as physical exercises, brain exercises, diet, mindfulness, yoga and the control of cardiovascular risk factors on dementia.
20. Are there mobile apps which can be used for improving cognitive ability?
21. Is SCA2 curable?
22. How many drugs are under trial currently?
Lecanemab – A phase 3 clinical trial found that the medicine slowed cognitive decline in people with early Alzheimer’s disease by 27%. Lecanemab works by preventing amyloid plaques in the brain from clumping. It is under review by the FDA and could become available in 2023.
Saracatinib – A drug initially developed as a possible cancer treatment is now being tested for Alzheimer’s disease. In mice, the drug turned off a protein and this allowed synapses to start working again; the animals experienced a reversal of some memory loss. Human trials for Saracatinib as a possible Alzheimer’s disease treatment are now underway.